UK Trial invites participants to test NO nebulizer
By Future Medicine | February 12, 2022 | 0 Comments | 268 views
- The phase 2 CORVIS trial, which is underway in two clinical sites in the UK by the Medicines Evaluation Unit in Manchester and Tyne Hospitals NHS Foundation Trust, has invited participants to test a self-administered inhaled formulation of nitric oxide (NO) for adults with COPD or bronchiectasis. According to the trial investigators, the formulation, RESP301, releases NO into the lungs once it is inhaled through a nebulizer and that previous trials have shown it to be effective against several respiratory viruses including SARS-COV-2. The trial’s part 2 (expansion phase) aims to recruit at least 150 patients. At least 50 of these patients will receive a test dose of RESP301 during a screening visit.
441
Elevate your practice with our advanced AI-based CDSS Tool.Transform your practice now!
Try AIDE
Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.
